Loading clinical trials...
Loading clinical trials...
A Multi-center, Prospective, Observational Study of Analysis of Q Cell Markers in Patients With Newly Diagnosed Primary Glioblastoma (Phase IV)
The purpose of this study is to determine whether Q cells separated from the glioma sample are determinants in treatment response and prognosis of glioma patients
The unique markers of Qcell were screened using the method of genomics and proteomics, then these markers will be qualitatively and quantitatively evaluated in glioblastoma patients by comparing their relationship with overrall survival/progression-free survival and treatment response.
Age
18 - 70 years
Sex
ALL
Healthy Volunteers
No
Nanfang Glioma Centre
Guangzhou, Guangdong, China
Start Date
March 1, 2014
Primary Completion Date
December 1, 2016
Completion Date
March 1, 2017
Last Updated
January 28, 2014
240
ESTIMATED participants
Lead Sponsor
Nanfang Hospital, Southern Medical University
Collaborators
NCT00083512
NCT05099003
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT06860594